Ensysce Biosciences closes $21 million first tranche, seeks Nasdaq grace period
Ensysce Biosciences said its first tranche of a Series C Preferred Stock financing, totaling roughly $43 million, closed on August 7, 2026, raising more than $21 million in gross proceeds. The company believes this restores compliance with Nasdaq's minimum stockholders' equity requirement and that it qualifies for a second 180-day grace period to regain compliance with the $1.00 bid price rule.
Key points
- First tranche closed August 7, 2026, raising more than $21 million gross; total financing is about $43 million for 120,260 Series C Preferred shares
- Second tranche depends on a clinical trial milestone that has not yet occurred
- Company believes stockholders' equity is at least $2.5 million, meeting the Nasdaq Rule 5550(b)(1) requirement, pending Nasdaq confirmation
- Second 180-day bid price grace period was requested from Nasdaq on August 24, 2026; Nasdaq response is pending
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.